Heparin Increases HLA-G Levels in Primary Antiphospholipid Syndrome by Carvalho, Jozelio Freire de et al.
  Universidade de São Paulo
 
2012
 
Heparin Increases HLA-G Levels in Primary
Antiphospholipid Syndrome
 
 
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, NEW YORK, v. 2012, pp. 29-35, MAY, 2012
http://www.producao.usp.br/handle/BDPI/41953
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Clínica Médica - FM/MCM Artigos e Materiais de Revistas Científicas - FM/MCM
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 232390, 5 pages
doi:10.1155/2012/232390
Clinical Study
Heparin Increases HLA-G Levels in Primary
Antiphospholipid Syndrome
Joze´lio Freire de Carvalho,1 RicardoM. de Oliveira,2 Carlos EwertonMaia Rodrigues,1
Andre´a Glezer,3 Eloı´sa Bonfa´,1 and RosaMaria Rodrigues Pereira1
1Reumatologia Divisa˜o, Faculdade de Medicina, Universidade de Sa˜o Paulo, Sala 3105, Avenida Dr. Arnaldo, 455,
01246-903 Sa˜o Paulo, SP, Brazil
2 Laborato´rio Cl´ınico, RDO Diagno´sticos, Avenida Brasil 1150, 01430-001 Sa˜o Paulo, SP, Brazil
3 Edocrinologia Divisa˜o, Hospital das Clinicas da Faculdade de Medicina, Universidade de Sa˜o Paulo, Avenida Dr Ene´as de Carvalho
Aguiar 44, 05403-000 Sa˜o Paulo, SP, Brazil
Correspondence should be addressed to Joze´lio Freire de Carvalho, jotafc@gmail.com
and Rosa Maria Rodrigues Pereira, rosamariarp@yahoo.com
Received 22 December 2011; Revised 3 March 2012; Accepted 5 March 2012
Academic Editor: E. Shevach
Copyright © 2012 Joze´lio Freire de Carvalho et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Objectives. The aim of this study was to investigate the HLA-G serum levels in Primary Antiphospholipid Syndrome (PAPS)
patients, its impact on clinical and laboratory findings, and heparin treatment. Methods. Forty-four PAPS patients were age and
gender matched with 43 controls. HLA-G serum levels were measured using an enzyme-linked immunosorbent assay (ELISA).
Results. An increase in soluble HLA-G levels was found in patients compared to controls (3.35 (0–22.9) versus 1.1 (0–14),
P = 0.017). There were no significant diﬀerences in HLA-G levels between patients with and without obstetric events, arterial
thrombosis, venous thrombosis, or stroke. Sixty-six percent of patients were being treated with heparin. Interestingly, patients
treated with heparin had higher HLA-G levels than ones who were not treated with this medication (5 (0–22.9) versus 1.8 (0–
16) ng/mL, P = 0.038). Furthermore, patients on heparin who experienced obstetric events had a trend to increased HLA-G levels
compared to patients who were not on heparin and did not have obstetric events (5.8 (0–22.9) versus 2 (0–15.2) ng/mL, P = 0.05).
Conclusion. This is the first study to demonstrate that serum HLA-G levels are increased in APS patients. We also demonstrated
that heparin increases HLA-G levels and may increase tolerance towards autoantigens.
1. Introduction
Human leukocyte antigen- (HLA-) G is a nonclassical HLA
class Ib molecule from the major histocompatibility com-
plex. It was originally discovered in the context of protecting
a fetus from the mother’s immune system [1]. Indeed, HLA-
G seems to be involved in the induction and maintenance
of tolerance between the mother’s immune system and the
semiallogeneic fetus at the fetal-placental interface; it also
seems to play an important role in embryo implantation
[2]. Beyond its role in fetal-maternal tolerance, HLA-G
exerts tolerogenic functions in transplant acceptance and
in tumoral and viral immune escape [1]. HLA-G antigens
can aﬀect the cytotoxicity of natural killer and CD8+ T
cells, CD4+ T-lymphocyte functions, and dendritic cell
maturation [3].
Recent studies have demonstrated the altered expression
of HLA-G in autoimmune diseases, such asmultiple sclerosis,
rheumatoid arthritis, and systemic lupus erythematosus
(SLE), suggesting a role for this molecule in the pathophysio-
logy of autoimmune diseases [4–7]. Antiphospholipid syn-
drome (APS) is an autoimmune disease frequently associated
with obstetric complications including fetal loss, recurrent
spontaneous abortions, and placental insuﬃciency. Conse-
quently, alterations in the HLA-G system might be a possible
mechanism involved in the etiology of this autoimmune
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disorder. However, there is no other study that evaluated
HLA-G levels in APS patients. This report represents the first
investigation of the role of HLA-G in APS.
The present study was therefore undertaken to determine
the serum HLA-G levels in patients with PAPS and to under-
stand the possible associations between HLA-G levels and
clinical and laboratory findings in PAPS.
2. Methods
2.1. Patients. This is a cross-sectional study that included 44
patients with PAPS, according to Sapporo criteria [8], and 43
age- and race-matched healthy subjects who served as con-
trols. All patients were followed at the Antiphospholipid Syn-
drome Outpatient Clinic within the Division of Rheumatol-
ogy at the Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo.
Patients who had secondary causes of APS, such as SLE,
rheumatoid arthritis (RA), or vasculitis, were excluded from
this study.
All subjects provided informed consent, and the study
was approved by the Ethics Committee of the University Hos-
pital.
2.2. Data Collection. Demographic data for patients and
controls were obtained through interviews and physical
examinations. Variables collected included age in years, gen-
der, race, and weight. Clinical and therapeutic data, including
disease duration, thrombotic and obstetric manifestations,
and medication history including administration of war-
farin, heparin, aspirin, anticonvulsants, and antimalarials,
were obtained from the medical records and interviews.
2.3. Measurement of sHLA-G. Capture enzyme-linked im-
munosorbent assay (ELISA) was used tomeasureHLA-G lev-
els. Briefly, 96-well microplates (Nunc-C8MaxiSorp BreakA-
part Immunomodule, Roskilde, Denmark) were coated for
72 h with 100 µL/well of monoclonal antibody MEM-G/9
(MCA2004-Serotec, Raleigh-NC, USA) in 10 µg/mL BBS
(pH 8.4) and incubated at 4◦C. After three washes with
PBS, 200 µL of a solution containing 5% bovine serum and
10% sucrose in PBS was added to the wells, and the plates
were incubated for 12 h at 4◦C. Before use, this solution was
aspirated, and plates were incubated for 2 h at 37◦C. Fifty µL
of calibration solution (diluted to 0, 3.125, 6.25, 12.5, and
25.0 ng/mL) from JEG-3 cells (human placental choriocar-
cinoma), or sera from patients and controls (undiluted),
was added in duplicate and followed by an incubation for
2 h at room temperature (RT). After three washings with
PBS, 50 µL of a peroxidase-conjugated IgG fraction of rabbit
anti-beta-2-microglobulin (Rockland Inc., Gilbertsville, PA,
US), diluted 1 : 500 in PBS with 10% normal rabbit serum,
was added and incubated for 1 h at RT. The reaction was
developed with 100 µL of TMB, and after 30min the reaction
was stopped with H2SO4 1N. Plates were read at an optical
density (OD) of 450 nm (EL Universal Microplate Reader,
BioTek Instruments Inc., Winooski, VT, USA). HLA-G levels
were calculated using a standard curve and results were
expressed in ng/mL [9, 10]. The intra-assay CV was 3.2 to
6.9% and the interassay 7.7 to 13.9%.
2.4. Antiphospholipid Antibodies. IgG and IgM anticardi-
olipin antibodies (aCL) were tested at least twice, with an in-
terval of 12 weeks between measurements, using an ELISA as
previously described [11]. According to the manufacturer’s
recommendations, only titers of aCL > 20U/mLwere consid-
ered positive. Lupus anticoagulant was measured according
to international guidelines using activated partial thrombo-
plastin time (APTT, Diagnostica Stago, France) and diluted
Russell’s viper venom time (dRVVT, Trinity Biotech, Wick-
low, Ireland) [12].
2.5. Statistical Analysis. Data are reported as a median (mini-
mum-maximum) for HLA-G serum levels, mean (± stan-
dard deviation), or a percent. Variables were compared be-
tween patients and controls using Student’s t-test or the Chi-
square test. P values < 0.05 were considered significant.
3. Results
Patients and controls were similar in terms of age (42.5 ±
12.0 versus 39.8 ± 11.2 years, P = 0.29, t-test), frequency of
female gender (86.4 versus 78.9%, P = 0.47, Chi-square test),
and Caucasian race (90.9 versus 84.2%, P = 0.42, Chi-square
test). Mean disease duration was 97.9± 70.3 months.
Arterial thrombosis was observed in 59.1% of patients,
venous thrombosis in 59.1%, obstetric events in 38.6%,
thrombocytopenia in 18.2%, livedo reticularis in 34.1%,
stroke in 43.2%, Sneddon’s syndrome in 24.5%, pulmonary
thromboembolism in 27.3%, deep venous thrombosis in
54.5%, and angina in 9.1%. In patients with PAPS, 38.6%
reported prior smoking history and 11.4% were current
smokers (Table 1). Lupus anticoagulant was positive in
60.5% of patients, IgG anticardiolipin in 36.8%, and IgM
anticardiolipin antibodies in 10.5%. Sixty-six percent of
patients were being treated with heparin, and 40.9% were
being treated with chloroquine diphosphate.
Notably, significantly increased levels of soluble HLA-G
were noted in PAPS patients compared to controls (3.35 (0–
22.9) versus 1.1 (0–14), P = 0.017, Mann-Whitney test)
(Table 1, Figure 1). Serum HLA-G levels were similar in
patients with and without obstetric events, arterial thrombo-
sis, venous events, and stroke (P > 0.05) (Mann-Whitney
test) (Table 2).
Interestingly, patients taking heparin had higher HLA-
G levels than subjects who were not using this medication
(5 (0–22.9) versus 1.8 (0–16) ng/mL, P = 0.038, Mann-
Whitney test) (Figure 1). Furthermore, patients taking hep-
arin who had obstetric events (n = 13) had a trend to in-
creased levels of HLA-G compared to other patients (n = 25)
(5.8 (0–22.9) versus 2 (0–15.2) ng/mL, P = 0.05, Mann-
Whitney test).
Patients taking heparin who experienced arterial throm-
bosis (n = 16) had similar levels of HLA-G compared
to the other patients (n = 28) (4.55 (0–15.2) versus
3.2 (0–22.9) ng/mL, P = 0.557, Mann-Whitney test), and
patients taking heparin who experienced venous thrombosis
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Table 1: Demographic, anthropometric, clinical, and laboratory features of the 44 PAPS patients and 43 healthy controls that provided
samples for the measurement of HLA-G levels.
PAPS
n = 44
Controls
n = 43 P
Age, years 42.47 (12.0) 39.83 (11.2) 0.29
White race, % 90.9 84.2 0.42
Arterial events, % 59.1 NA —
Venous events, % 59.1 NA —
Obstetric events, % 38.6 NA —
Thrombocytopenia, % 18.2 NA —
Livedo reticularis, % 34.1 NA
Stroke, % 43.2 NA —
Sneddon’s syndrome, % 24.5 NA —
Pulmonary thromboembolism, % 27.3 NA —
Deep venous thrombosis, % 54.5 NA —
Angina, % 9.1 NA
Disease duration, months 97.9 (70.3) NA —
Previous history of smoking, % 38.6 NA —
Current smoking, % 11.4 NA —
Heparin use, % 66 NA —
Current chloroquine use, % 40.9 NA —
HLA-G, ng/mL# 3.35 (0–22.9) 1.1 (0–14) 0.017
NA: not applicable.
Data expressed as a mean (standard deviation), #median (minimum-maximum), or a percentage.
Table 2: Comparison of HLA-G levels between primary antiphospholipid syndrome patients (PAPS) with and without clinical events.
HLA-G levels in PAPS with clinical events HLA-G levels in PAPS without clinical events P
Obstetric event 5.4 (0–22.9) 2.0 (0–15.2) 0.206
Arterial event 2.5 (0–15.2) 4.8 (0–22.9) 0.304
Venous event 2.9 (0–22.9) 4.15 (0–15.2) 0.574
Stroke 2.4 (0–16) 5 (0–22.9) 0.18
Data expressed as a median (minimum-maximum) in ng/mL.
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Figure 1: HLA-G serum levels in 44 PAPS patients and 43 healthy
controls, and in PAPS patients with and without heparin.
(n = 18) had comparable levels of HLA-G compared to the
others (n = 26) (3.6 (0–22.9) versus 3.35 (0–15.9) ng/mL,
P = 0.990, Mann-Whitney test).
4. Discussion
This is the first study to demonstrate higher levels of HLA-G
in PAPS patients compared to healthy subjects.
One advantage of this study was the inclusion of
exclusively primary APS patients because it is clear that SLE
can alter HLA-G levels [6, 7]. Indeed, previous studies of
HLA-G in SLE have presented conflicting results [6, 7, 13].
Lower plasma levels of soluble HLA-G were more frequent
in patients with SLE [6]. Wu et al. [13] demonstrated a signi-
ficant increase in the expression of soluble HLA-G in patients
with SLE; high levels of soluble HLA-G were also associated
with more active disease and more neurologic involvement.
It is possible that enhanced expression of soluble HLA-G in
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SLE contributes to a mechanism that restores tolerance tow-
ards autoantigens and counteracts inflammation. However,
the participation of this molecule in the pathologic process
of SLE has not been excluded. Thus, environmental and/or
ethnicity-specific factors may be contributing to such con-
flicting results.
Recent studies have demonstrated that HLA-G is induced
with the development of inflammatory pathologies such
as myositic lesions, psoriatic lesions on skin, and multiple
sclerosis [4, 14, 15]. Furthermore, HLA-G expression on the
surface of epithelial intestinal cells seems to play a role in
the suppression of proinflammatory cytokines in ulcerative
colitis [16]. It has been suggested that HLA-G expres-
sion plays a role in a possible mechanism of tissue protection
against autoimmune inflammatory responses, therefore act-
ing as a mechanism of immune surveillance [17, 18]. In this
regard, a combination of genes, instead of a single gene, pre-
disposes one to an immunologic disorder that leads to defec-
tive mechanisms of immunological tolerance, allowing anti-
body production against autoantigens, immune complex for-
mation, and deposition [19].
Our study provided an opportunity to assess the possible
connections between PAPS and HLA-G levels. While we de-
monstrated that HLA-G levels are increased in PAPS patients,
we did not observe a diﬀerence in the HLA-G levels in
patients who had clinical manifestations of PAPS, including
obstetric events.
Recent evidence suggests that HLA-G may be involved in
the suppression of immune responses including inhibition of
the proliferation of CD4+ T cells, induction of CD4+ T-cell
anergy, and diﬀerentiation of CD4+ T cells into suppressive
cells [20]. A similar process was suggested to explain the
higher soluble HLA-G expression in correlation with RA dis-
ease activity [21].
One possible explanation is that heparin could increase
HLA-G expression on target tissues. In fact, Baczyk et al.
demonstrated that heparin plus fibroblast growth factor 4
(FGF4) induced an increase of HLA-G expression with more
invasiveness of trophoblast tissue [22].
The most interesting finding in this study was that
patients taking heparin had higher HLA-G than patients who
were not treated with this medication. Furthermore, patients
on heparin who experienced obstetric events had a trend to
increased levels of HLA-G compared to patients not taking
heparin who did not have obstetric events. These findings
suggest a possible enhanced expression of soluble HLA-G in
PAPS as part of a mechanism to restore the tolerance process
towards autoantigens; it also demonstrates that hepar-
in increases HLA-G levels and may increase this immuno-
logic aberrancy. Kovats et al. [2] demonstrated that HLA-G
is expressed in cytotrophoblasts. They identified a molecule
and a gene that could be involved in placental-maternal inter-
action and could be studied quantitatively and qualitatively
in connection with certain types of unexplained infertility
and spontaneous abortion [23].
In summary, this study demonstrated higher levels of
HLA-G in PAPS, particularly in patients with obstetric
events. We also demonstrated that heparin increases HLA-G
levels and may increase tolerance towards autoantigens.
5. Rheumatology KeyMessages
(i) Serum HLA-G levels are increased in antiphospho-
lipid syndrome patients in comparison to healthy
controls.
(ii) Heparin treatment increases HLA-G levels in
antiphospholipid syndrome patients with obstetric
events.
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